Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Troriluzole (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms T2 Protect AD
  • Sponsors Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals

    • Most Recent Events

    • 20 Jul 2023 Results of post-hoc analyses, examining whether plasma biomarkers (Ab1-40, Ab1-42, total tau, p-tau-181, NfL, and GFAP) predicted 48-week change in cognitive (ADAS-Cog11), global function (CDR-SB), and volumetric MRI (6 cortical regions and 2 whole brain measures) outcomes in this study, presented at the Alzheimer's Association International Conference 2023
    • 15 Feb 2022 Status changed from active, no longer recruiting to completed.
    • 18 Jan 2021 According to a Biohaven Pharmaceutical media release, the company is planning to amend the ongoing long-term extension study of troriluzole in AD for mild AD patients to be able to continue treatment in order to gather additional clinical and biomarker data.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top